Patient # | Diagnosis | Age at cytarabine initiation (years) | Gender | Sites of disease | Gene mutations | Previous therapies | Total number of cytarabine cycles | Response | Progression or disease recurrence? (time from start of therapy to relapse) | Follow-up duration (months) | Maintenance or recurrent treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | ECD | 45 | F | CNS, bones, pituitary | None-detected | None | 4 | PR | No | 48 | Interferon-α |
2 | ECD | 24 | F | CNS, bones, obit, lung, retroperitoneum | BRAF V600E | None | 4 | PR | No | 39 | Interferon-α |
3 | ECD | 56 | M | bones, vasculature, orbit, lung, nasal sinus, retroperitoneum | BRAF V600E | Interferon-α | 6 | PR | No | 13 | Interferon-α |
4 | ECD | 36 | F | bones, vasculature, orbit, thyroid, pericardium, retroperitoneum | None-detected | Interferon-α | 4 | PD | Yes (5 months) | 12 | Sirolimus/prednisone |
5 | ECD | 50 | M | CNS, bones, pituitary, thyroid, vasculature, nerve root | NA | None | 6 | PR | No | 17 | Interferon-α |
6 | ECD | 51 | F | CNS, bones | BRAF V600E | None | 6 | PR | Yes (19 months) | 25 | Interferon-α → vemurafenib |
7 | ECD | 53 | F | Bones, heart, pericardium | BRAF V600E | Interferon-α | 2 | PD (died) | Yes (6 months) | 6 | NA |
8 | ECD | 51 | F | CNS, bones, skin, thyroid, retroperitoneum, pancreas | None-detected | None | 4 | PR | No | 9 | Interferon-α |
9 | ECD | 52 | M | CNS, Bone, pericardium, orbit, retroperitoneum, vasculature, lung | None-detected | Interferon-α | 5 | PR | No | 68 | Interferon-α |
10 | ICH | 22 | M | Bones, CNS (Spinal cord) | NA | None | 6 | PR | No | 14 | NA |
11 | RDD | 34 | M | CNS | None-detected | None | 6 | PR | No | 23 | Lenalidomide/dexamethasone |
12 | RDD | 37 | M | CNS, dura | NA | Surgery | 6 | CR | No | 12 | NA |
13 | RDD | 70 | M | Bones, orbit, nasal sinus, glottis | BRAF R188G MAP2K1D147G1 | Methylprednisolone | 4 | PR | No | 8 | Lenalidomide/dexamethasone |
14 | RDD | 18 | M | CNS, pituitary | BRAF V600E wild type | None | 6 | PR | No | 61 | Interferon-α |
15 | RDD | 50 | M | CNS, dura | NA | Methylprednisolone/Rituximab | 6 | PR | No | 60 | Interferon-α |
16 | Unclassified histiocytosis | 22 | M | Bones, skin, gingiva | NA | COP, CHOP, lenalidomide | 3 | PR | No | 6 | NA |